Cysteine protease inhibitors have been described as cytostatic agents working as inhibitors of metastasis in many neoplasias, among them in pancreatic cancer cell lines. These cells overexpress cysteine proteases. In this Project, in vitro assays using the pancreatic cell line (MIA PaCa-2) and Balb/C 3T3 clone A31 mouse fibroblasts will be used to determine the selectivity profile for a set of compounds synthesized by the NEQUIMED group. Moreover, several assays like proteolytic activity in cells, clonogenic assay cell replication and wound healing will be applied to understand how these substances modulate the cell response. Therefore, the pharmacological profile for the dipeptidyl nitrile derivatives will be accessed to select the most promising compounds for the optimization of potency and pharmacokinetics/toxic properties.
News published in Agência FAPESP Newsletter about the scholarship: